Medical/Pharmaceuticals

OLON ANNOUNCES THE CREATION OF A MAJOR CENTER OF RESEARCH AND DEVELOPMENT IN ITALY, THAT WILL GIVE RISE TO AN INNOVATIVE GLOBAL R&D MODEL

MILAN, May 26, 2022 /PRNewswire/ -- Olon, Leading API supplier, announces the creation of an R&D hub at its center inMilan, home to the Group's headquarters, paving the way for further major expansion and diversification of its expertise applied to the development of APIs for the CDMO and Generic...

2022-05-26 19:00 1703

111 to Announce First Quarter 2022 Unaudited Financial Results on June 16, 2022 - Conference Call to Follow

SHANGHAI, May 26, 2022 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced that it will report its unaudited financial results ...

2022-05-26 16:59 3118

"To China, Empower Your Shared Future" the 2nd Round of CIIE Medtech Roadshow Open for Application Now

SHANGHAI, May 26, 2022 /PRNewswire/ -- "To China, Empower Your Shared Future" the 2nd CIIE Innovation Incubation Area - one of the most distinguished medtech trade show inChina has been officially launched since March, 2022. On the China International Import Expo (CIIE) platform, CIIE Innovation ...

2022-05-26 15:44 2068

Full-Life Technologies Completes $37 Million (USD) Series A Financing to Accelerate Development of its Radiopharmaceutical Pipeline and Radiotechnology Production Platform

SHANGHAI and BRUSSELS, May 26, 2022 /PRNewswire/ -- Full-Life Technologies ("Full-Life") today announced it completed a$37 million (USD) Series A financing round to advance the development of its radiopharmaceutical oncology product pipeline and its radiotechnology production platform. The financ...

2022-05-26 12:00 1526

DeepGI AI - A Thai Innovation for the Precision in Colorectal Polyp Detection

BANGKOK, May 26, 2022 /PRNewswire/ -- Chula Engineering and Chula Medicine co- invent an innovative device for a rapid gastrointestinal cancer detection that yields accurate results hoping to foster preventive medicine in gastrointestinal malignancy and reduce the number of cancer patients.

2022-05-26 10:10 2410

Servier Announces FDA Approval of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine for Patients with Newly Diagnosed IDH1-mutated Acute Myeloid Leukemia

TIBSOVO is the first therapy targeting cancer metabolism approved in combination with azacitidine for patients with newly diagnosed IDH1-mutated acute myeloid leukemia FDA approval based on data from the global, Phase 3 AGILE trial that demonstrated a statistically significant improvement in eve...

2022-05-26 08:07 2599

Servier Announces FDA Approval of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine for Patients with Newly Diagnosed IDH1-mutated Acute Myeloid Leukemia

TIBSOVO is the first therapy targeting cancer metabolism approved in combination with azacitidine for patients with newly diagnosed IDH1-mutated acute myeloid leukemia FDA approval based on data from the global, Phase 3 AGILE trial that demonstrated a statistically significant improvement in eve...

2022-05-26 04:45 1825

TikoMed AB reports positive phase II clinical data for the treatment of Amyothropic Lateral Sclerosis in data published by PLOS ONE

STOCKHOLM, May 26, 2022 /PRNewswire/ -- A new study with TikoMed's platform lead clinical drug candidate ILB®, provides positive safety and tolerability results and the first clinical evidence of encouraging clinical efficacy of ILB® in the treatment of amyotrophic lateral sclerosis (ALS). The st...

2022-05-26 03:40 1919

Golden Meditech Stem Cells Responds to Unfounded Accusations

HONG KONG, May 25, 2022 /PRNewswire/ -- On May 25, 2022, Golden Meditech Stem Cells (BVI) Company Limited (the "Company"), would like to respond to the accusations made against the Company in relation to the Company's enforcement of its rights under the Share Charge Agreement between the Company ...

2022-05-25 23:18 3265

Excelra Partners with HotSpot Therapeutics to Enhance Allosteric Drug Discovery Efforts

HYDERABAD, India and BOSTON, May 25, 2022 /PRNewswire/ -- Excelra, a leading global data and digital insights organization, today announced a partnership with HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of small molecule allosteric therapies for th...

2022-05-25 23:04 2833

The Centre for Probe Development and Commercialization expands into Asia and executes a development, manufacturing, and clinical supply agreement for 177Lu-PSMA (DGUL) With South Korea-based CellBion

HAMILTON, ON, May 25, 2022 /PRNewswire/ -- The Centre for Probe Development and Commercialization (CPDC) is pleased to announce the initiation of a development, manufacturing, and supply agreement withCellBion for Lu-177-radiolabelled PSMA (DGUL) therapeutic agent. Under the terms of the agreeme...

2022-05-25 21:00 1335

SeekIn Receives CE Mark Approval for SeekInClarity™ Cancer Treatment Response Monitoring Kit

First-of-its-Kind blood-based pan-cancer treatment response monitoring test SHENZHEN, China, May 25, 2022 /PRNewswire/ -- SeekIn Inc, a leader in blood-based cancer early detection and monitoring technology, today announced CE (ConformitéEuropéenne) Mark approval for SeekInClarityTM Cancer Treatm...

2022-05-25 20:30 1771

Seegene unveils '$12 PCR testing' initiative to help end COVID-19 pandemic

Includes asymptomatic testing at community-based facilities to prevent widespread transmissions Regular testing for COVID-19, flu, RSV crucial for staying safe as anti-virus restrictions are eased PCR tests will be priced affordably, made possible through Seegene's 20 years of expertise "Full ...

2022-05-25 19:00 2161

Harbour BioMed Announces Dosing of First Patient in Phase I Trial of B7H4x4-1BB Bispecific Antibody

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, May 25, 2022 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) announcedthat it has successfully completed the dosing of first patient in phase I trial of B7H4x4-1BB bispecific antibody HBM7008 inAustralia. This study will evaluate ...

2022-05-25 17:42 1693

Dr Ivan Puah Expands Service To Sports Aesthetics® To Meet Demands Of Sportspeople

Sports aesthetics® is a term coined by Dr Ivan Puah based on the three pillars of combining unique service offerings to help fitness enthusiasts, sportspeople and professional athletes attain their ideal physiques without compromising the quality of their physical health. SINGAPORE, May 25,...

2022-05-25 16:07 2187

DoctorOnCall Inks MoU with (Pertubuhan Doktor-Doktor Islam Malaysia) PERDIM to Bridge Healthcare Providers and Patients Through Digital Platform

The partnership will propel PERDIM's digital healthcare capabilities and increase revenue by offering an online database of healthcare products, services and treatments across the nation. KUALA LUMPUR, Malaysia, May 25, 2022 /PRNewswire/ -- Malaysia's first and largest digital health platform, H...

2022-05-25 11:08 2950

Brii Biosciences to be Added to MSCI China Small Cap Index

DURHAM, N.C. and BEIJING, May 25, 2022 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) today announced that it will be added to the MSCI China Small Cap Index, effective as ofHong Kong market close on May 31, 2022. ...

2022-05-25 08:00 4281

CJ BIO and NatureWorks Working Towards a Master Collaboration Agreement to Commercialize Novel Biopolymer Solutions

Companies announce signed letter of intent to collaborate on creating advanced products based on industry-leading Ingeo™ PLA and PHACT® PHA technologies to meet growing demand for sustainable materials across wide array of markets WOBURN, Mass. and PLYMOUTH, Minn., May 25, 2022 /PRNewswire/ -- CJ...

2022-05-25 07:00 2410

Insilico Medicine Announces Novel 3CL Protease Inhibitor Preclinical Candidate for COVID-19 Treatment

* Insilico's candidate demonstrated a favorable profile with good in vivo efficacy at low doses, efficient synthesis, and no need for co-administration with Ritonavir. * The candidate is intended to be used for the treatment of SARS-CoV-2 and its variants, along with other coronaviruses. * ...

2022-05-25 05:00 2223

Vision Impact Institute Joins Partners to Bring Good Vision to Vulnerable Populations in Panama

Joint effort will expand access to vision care and deliver free eye care and services DALLAS, May 25, 2022 /PRNewswire/ -- The Vision Impact Institute (VII) is pleased to join a partnership that brings eye care services to vulnerable populations inPanama. The partnership includes Lions Club Peno...

2022-05-25 03:34 2175
1 ... 244245246247248249250 ... 577